Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.69
- Piotroski Score 2.00
- Grade Buy
- Symbol (CLSD)
- Company Clearside Biomedical, Inc.
- Price $1.11
- Changes Percentage (1.83%)
- Change $0.02
- Day Low $1.08
- Day High $1.16
- Year High $2.12
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.55
- Trailing P/E Ratio -2.22
- Forward P/E Ratio -2.22
- P/E Growth -2.22
- Net Income $-32,485,000
Income Statement
Quarterly
Annual
Latest News of CLSD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Even after rising 13% this past week, Clearside Biomedical (NASDAQ:CLSD) shareholders are still down 77% over the past three years
Despite Clearside Biomedical, Inc.'s recent 13% share price increase, its three-year returns show a significant decline of 77%. The company's revenue has been shrinking by 38% annually, impacting its ...
By Yahoo! Finance | 2 days ago
